Sutro Biopharma, Inc. (STRO) stock

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 7/30

$10.26+0.09 (+0.88%)

Close on Nov 11, 2026Market cap $170.12MP/E –Yield –

Sutro Biopharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Sutro Biopharma's price to sales ratio was 3.7× on Nov 11, 2026, against 0.7× a year earlier. Over the last 5 years it ranged from 0.7× to 11.6×, with a median of 3.6×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	3.7×	+2.8
2025	Dec 31, 2025	0.9×	−0.0
2024	Dec 31, 2024	0.9×	−4.4
2023	Dec 29, 2023	5.4×	−1.0
2022	Dec 30, 2022	6.3×	−5.2
2021	Dec 31, 2021	11.6×	−6.5
2020	Dec 31, 2020	18.1×	+13.0
2019	Dec 31, 2019	5.0×	+4.8
2018	Dec 31, 2018	0.2×	–

Where these numbers come from

Parsed from the XBRL in Sutro Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 3, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing